ClinicalTrials.gg
Not yet recruitingNCT07429396Updated Feb 24, 2026

Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure, Heart Failure, Diastolic and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Instituto Politécnico de Leiria. Not yet recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Primary conditionHeart Failure, DiastolicRegistry: Heart FailureReclassifiedWhy we changed it
Registry
Heart Failure — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure, Diastolic
Why
  1. The study's listed conditions name Heart Failure, Diastolic, a narrower term within Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Instituto Politécnico de Leiria · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn how people with Heart Failure with Preserved Ejection Fraction (HFpEF) can be grouped into different "phenotypes" based on their clinical information. The researchers want to understand whether these groups have different health profiles and different responses during a cardiopulmonary exercise test (CPET).

The main questions this study aims to answer are:

  • Can clinical data be used to identify meaningful HFpEF phenotypes?
  • Do these phenotypes match well-known HFpEF scores, such as the H2FPEF and Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide (HFA-PEFF) scores?
  • Do people in different phenotypes show different results on a CPET?

Participants will:

  • Have their past clinical records reviewed if they were diagnosed with HFpEF at the Local Health Unit of the Leiria Region (ULS RL);
  • A smaller group will attend one visit to complete a CPET, which measures how the heart, lungs and muscles respond during exercise.

This study includes adults aged 18 years or older who have HFpEF. The study does not involve any new treatments or experimental drugs.

Read the detailed description

Heart Failure with Preserved Ejection Fraction (HFpEF) is a complex condition, and people with HFpEF can have different symptoms and clinical profiles. Understanding these differences may help improve how the condition is described and studied. This study has two parts: a retrospective analysis and a cross-sectional assessment.

In the retrospective part, the researchers will collect clinical information that was previously recorded in the hospital's clinical records during past hospitalizations for HFpEF at the Local Health Unit of the Leiria Region (ULS RL). The data will be reviewed and prepared for analysis using standard data quality procedures. After the database is complete, the researchers will use data-driven methods to look for patterns among participants, in order to identify groups of people who share similar characteristics ("phenotypes") without setting predefined categories. Methods will include descriptive statistics, correlation analysis and feature selection using algorithmic approaches such as ReliefF. For phenotyping, unsupervised machine-learning techniques including K-means clustering and principal component analysis (PCA) will be applied.

The cross-sectional part will invite a sample of participants selected to represent each phenotype (planned 15 participants for each phenotype) identified in the retrospective analysis. Selected participants will complete a single on-site visit including informed consent verification, a structured clinical review and a standardized cardiopulmonary exercise test (CPET) performed according to local and international guidelines. The CPET procedures will follow the laboratory protocol, namely calibration of equipment, resting measurements, incremental workload protocol, continuous gas exchange, and electrocardiogram (ECG) monitoring. CPET data will be recorded in digital format and transferred securely to the study database.

The study will also evaluate phenotype concordance with widely used HFpEF tools (H2FPEF and HFA-PEFF) and describe differences in physiological responses during CPET across phenotypes, to help clarify how useful they are in describing different forms of HFpEF. Analyses will emphasize exploratory, data-driven evaluation and estimation of effect sizes, consistent with the phenotyping objectives of the study. Where relevant, associations between phenotype membership and CPET variables will be explored descriptively and through correlation-based analyses.

Ethical and data protection procedures are in place. Personal identifiers will be removed and replaced by study ID codes. A linkage file (study ID to personal identifiers) will be stored on an encrypted device with access restricted to the student investigator. Electronic study data will be housed on secure servers with role-based access control. Data will be retained according to institutional policy and relevant legislation. Only de-identified datasets will be used for analysis and sharing. Safety procedures for CPET include pre-test screening for absolute contraindications, continuous ECG and blood pressure monitoring during the test, availability of emergency equipment and immediate clinical oversight by qualified personnel. Adverse events during CPET will be recorded and reported per the Ethics Committee requirements.

By combining clinical record information collected during previous hospitalizations with detailed exercise testing in a selected group, this study aims to provide new insight into the variation that exists among people with HFpEF. The findings may support more personalized approaches in future research.

02

Conditions studied

  • Heart Failure
  • Heart Failure, Diastolic
  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Browse trials for

Keywords

  • Heart Failure
  • HFpEF
  • Preserved Ejection Fraction
  • Phenotyping
  • Machine Learning
  • Data-driven clustering
  • Cardiopulmonary Exercise Testing
  • H2FPEF score
  • HFA-PEFF score
  • Exercise tolerance
03

In context

Heart Failure, Diastolic Reclassified

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

This study's planned enrollment of 200 is close to the median of 200 across 55 observational studies indexed under Heart Failure, Diastolic.

Browse Heart Failure, Diastolic studies →

Lead sponsor

Instituto Politécnico de Leiria is the lead sponsor of 20 studies on the registry; 6 are open to participants now.

Compared within Heart Failure, Diastolic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (≥18 years) with a confirmed diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%) admitted in the Local Health Unit of the Leiria Region since September 2018. The retrospective phase includes electronic health records from approximately 200 patients, used to obtain multimodal datasets for unsupervised clustering. A cross-sectional phase recruits volunteer participants selected for representativeness of the identified phenotypes to undergo cardiopulmonary exercise testing (CPET) for functional characterization. Collected data include sociodemographic variables, clinical history, imaging findings, laboratory biomarkers (e.g., NT-proBNP), therapeutic data and CPET-derived functional parameters.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Retropective observational phase (Phase I):

    • Age ≥18 years;
    • Established diagnosis of heart failure with preserved (LVEF ≥50%);
    • Patients receiving care (outpatient or inpatient) at the Local Health Unit of the Leiria Region (ULS RL) since September 2018.
  2. Cross-sectional observational phase (Phase II - CPET):

    • Age ≥18 years;
    • Established diagnosis of HFpEF;
    • Selection as a volunteer representative of phenotypes identified in the retrospective clustering analysis;
    • Provision of written prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Retropective observational phase (Phase I):

    • Incomplete or inadequate medical records preventing full data extraction.
  2. Cross-sectional observational phase (Phase II - CPET):

    • Medical or physical inability to perform cardiopulmonary exercise testing (CPET);
    • Inability to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational HFpEF Cohort

    Single observational cohort including all adults with an established diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%) who received care at the Local Health Unit of the Leiria Region (ULS RL) since September 2018. Clinical, biochemical, imaging, functional, and therapeutic information recorded during previous hospitalizations will be extracted for retrospective analysis. A subset of participants will later be invited to complete a single cardiopulmonary exercise test (CPET) according to the study protocol. Phenotypes (clusters) will be identified post-hoc using unsupervised machine-learning methods and are not predefined at the time of enrollment.

06

What researchers measure

Primary outcomes

  1. Identification and characterization of HFpEF phenotypes using multimodal clustering analysis

    Identification of distinct phenotypic clusters in patients with heart failure with preserved ejection fraction using unsupervised machine learning applied to multimodal clinical, biochemical, imaging and functional data.

    Time frame: Up to December 2026 (completion of retrospective data collection and clustering analysis).

Secondary outcomes

  1. Mean peak oxygen uptake (VO₂peak) during cardiopulmonary exercise testing

    Peak oxygen uptake (VO₂peak), expressed in mL·kg-¹·min-¹, measured by breath-by-breath gas analysis during maximal cardiopulmonary exercise testing and compared across HFpEF phenotypes.

    Time frame: December 2026 to July 2027 (single assessment per participant).

  2. Concordance between H2FPEF and HFA-PEFF scores and identified HFpEF phenotypes

    Assessment of concordance and discrimination performance of H2FPEF and HFA-PEFF scores in identifying phenotypes derived from data-driven clustering.

    Time frame: Up to October 2027.

  3. Mean plasma NT-proBNP concentration (pg/mL) by HFpEF phenotypes

    Comparison of plasma NT-proBNP concentrations (pg/mL) between HFpEF phenotypes identified by clustering analysis.

    Time frame: Up to February 2028.

07

Study locations

2 sites
08

References and documents

Publications

  • Ferreira JP, Dewan P, Jhund PS, Lorenzo-Almoros A, Duarte K, Petrie MC, Carson PE, McKelvie R, Komajda M, Zile M, Zannad F, McMurray JJV. Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol. 2020 Nov;109(11):1358-1365. doi: 10.1007/s00392-020-01632-x. Epub 2020 Mar 25. PubMed 32215700 ↗
  • Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11. PubMed 19001508 ↗
  • Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, McMurray JJV, Pfeffer MA, Solomon SD. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 Aug;8(8):618-626. doi: 10.1016/j.jchf.2020.02.007. Epub 2020 May 6. PubMed 32387067 ↗
  • Pereira PMM, Thomaz LA, Tavora LMN, Assuncao PAA, Fonseca-Pinto RM, Paiva RP, Faria SMM. Melanoma classification using light-Fields with morlet scattering transform and CNN: Surface depth as a valuable tool to increase detection rate. Med Image Anal. 2022 Jan;75:102254. doi: 10.1016/j.media.2021.102254. Epub 2021 Oct 7. PubMed 34649195 ↗
  • Grote T, Berens P. Uncertainty, Evidence, and the Integration of Machine Learning into Medical Practice. J Med Philos. 2023 Feb 17;48(1):84-97. doi: 10.1093/jmp/jhac034. PubMed 36630292 ↗
  • Shehab M, Abualigah L, Shambour Q, Abu-Hashem MA, Shambour MKY, Alsalibi AI, Gandomi AH. Machine learning in medical applications: A review of state-of-the-art methods. Comput Biol Med. 2022 Jun;145:105458. doi: 10.1016/j.compbiomed.2022.105458. Epub 2022 Mar 28. PubMed 35364311 ↗
  • Quazi S. Retraction Note: Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2025 Apr 26;42(6):180. doi: 10.1007/s12032-025-02732-2. No abstract available. PubMed 40281258 ↗
  • Bayes-Genis A, Liu PP, Lanfear DE, de Boer RA, Gonzalez A, Thum T, Emdin M, Januzzi JL. Omics phenotyping in heart failure: the next frontier. Eur Heart J. 2020 Sep 21;41(36):3477-3484. doi: 10.1093/eurheartj/ehaa270. PubMed 32337540 ↗
  • Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. PubMed 31504452 ↗
  • Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018 Aug 28;138(9):861-870. doi: 10.1161/CIRCULATIONAHA.118.034646. PubMed 29792299 ↗
  • John JE, Claggett B, Skali H, Solomon SD, Cunningham JW, Matsushita K, Konety SH, Kitzman DW, Mosley TH, Clark D 3rd, Chang PP, Shah AM. Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study. J Am Heart Assoc. 2022 Sep 6;11(17):e021660. doi: 10.1161/JAHA.121.021660. Epub 2022 Aug 24. PubMed 36000416 ↗
  • Olaniyi KS, Atuma CL, Sabinari IW, Hadiza M, Saidi AO, Akintayo CO, Ajadi IO, Olatunji LA. Restoration of cardiac metabolic flexibility by acetate in high-fat diet-induced obesity is independent of ANP/BNP modulation. Can J Physiol Pharmacol. 2022 Jun 1;100(6):509-520. doi: 10.1139/cjpp-2021-0531. Epub 2022 Apr 8. PubMed 35395159 ↗
  • Brady PF, Chua W, Nehaj F, Connolly DL, Khashaba A, Purmah YJV, Ul-Qamar MJ, Thomas MR, Varma C, Schnabel RB, Zeller T, Fabritz L, Kirchhof PF. Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. J Am Heart Assoc. 2022 Feb 15;11(4):e022833. doi: 10.1161/JAHA.121.022833. Epub 2022 Feb 3. PubMed 35112889 ↗
  • Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. Eur Heart J. 2022 May 21;43(20):1952-1954. doi: 10.1093/eurheartj/ehac121. No abstract available. PubMed 35301541 ↗
  • Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884. PubMed 27358439 ↗
  • Glean AA, Ferguson SK, Holdsworth CT, Colburn TD, Wright JL, Fees AJ, Hageman KS, Poole DC, Musch TI. Effects of nitrite infusion on skeletal muscle vascular control during exercise in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1354-60. doi: 10.1152/ajpheart.00421.2015. Epub 2015 Sep 14. PubMed 26371165 ↗
  • Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015 Jan 27;131(4):371-80; discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957. Epub 2014 Dec 22. PubMed 25533966 ↗
  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5. No abstract available. PubMed 23747642 ↗
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. No abstract available. PubMed 27206819 ↗
  • Amanai S, Harada T, Kagami K, Yoshida K, Kato T, Wada N, Obokata M. The H2FPEF and HFA-PEFF algorithms for predicting exercise intolerance and abnormal hemodynamics in heart failure with preserved ejection fraction. Sci Rep. 2022 Jan 7;12(1):13. doi: 10.1038/s41598-021-03974-6. PubMed 34996984 ↗
  • Bilak JM, Alam U, Miller CA, McCann GP, Arnold JR, Kanagala P. Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. Card Fail Rev. 2022 Jul 1;8:e24. doi: 10.15420/cfr.2022.12. eCollection 2022 Jan. PubMed 35846985 ↗
  • Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol. 2020 Aug 26;12(8):373-408. doi: 10.4330/wjc.v12.i8.373. PubMed 32879702 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. The dataset contains sensitive clinical and physiological information, including cardiopulmonary exercise test (CPET) variables, with a high risk of reidentification even after de-identification procedures. Institutional policies, local ethics approval, and applicable data protection regulations do not permit external sharing of these data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 24, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
May 31, 2028
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07429396
Lead sponsor
Instituto Politécnico de Leiria
Collaborators
Faculty of Medicine of Universidade de Lisboa (FMUL), Hospital de Santo André, Fundação para a Ciência e a Tecnologia
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Feb 24, 2026

Study contacts

Sónia C Santos, MSc
Contact
sonia.c.santos@ipleiria.pt
+351910724415
Rui M Fonseca-Pinto, PhD
Contact
rui.pinto@ipleiria.pt
+351965632378
Rui M Fonseca-Pinto, PhD
study director · ciTechCare - Center for Innovative Care and Health Technology, Polytechnic of Leiria
João C A Morais, PhD
study director · ciTechCare - Center for Innovative Care and Health Technology, Polytechnic of Leiria
Vera L P Geraldes, PhD
study director · Faculty of Medicine, University of Lisbon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion